SVF
Level A· Stronger Clinical EvidenceSystematic Review

Comparative Efficacy and Safety of Intra-Articular Adipose-Derived, Bone Marrow-Derived, and Peripheral Blood-Derived Stem Cell Injections for Knee Osteoarthritis: A Systematic Review.

Jeon SY., Kim MW., Lee DH.

Systematic Review with a reported sample of 1247 on Knee Osteoarthritis, Osteoarthritis, published in Bioengineering (Basel) (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Bioengineering (Basel) (2026)
Country
Switzerland
Reported sample size
1247
PMID
42510437
DOI
10.3390/bioengineering13070771

Abstract (original English)

Background : Intra-articular (IA) stem cell injection is an emerging treatment for knee osteoarthritis (KOA). Three principal cell sources-adipose-derived mesenchymal stem cells (ADMSCs), bone marrow-derived MSCs (BMMSCs), and peripheral blood-derived stem cells (PBSCs)-have been evaluated independently; however, a systematic review comprehensively comparing all three sources under unified eligibility criteria is absent from the literature. Methods : Systematic searches of MEDLINE, Embase, Cochrane CENTRAL, and Scopus were conducted from inception to December 2025, supplemented by manual reference screening and ClinicalTrials.gov. Eligible studies included randomized controlled trials (RCTs) and prospective comparative studies in adult KOA patients. Primary outcomes were pain (VAS/NRS) and function (WOMAC, KOOS) at ≥3 months. Risk of bias was assessed using RoB 2 and ROBINS-I; evidence certainty was rated using GRADE. Results : Thirty-one studies ( n = 1247; ADMSC: 14 studies, n = 612; BMMSC: 12 studies, n = 487; PBSC: 5 studies, n = 148) met inclusion criteria. Pooled standardized mean differences (SMDs) for 6-month pain showed significant reduction versus comparators for ADMSCs (SMD -1.23; 95% CI -1.61 to -0.85; I 2 = 62%) and BMMSCs (SMD -1.09; 95% CI -1.55 to -0.63; I 2 = 70%). PBSCs demonstrated significant within-group improvement but were too few for formal pooling. Beca

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
KneeKnee OsteoarthritisOsteoarthritis
View on PubMedDOI

Related research